ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ALCOR Biocorp

35.10
0.00 (0.00%)
14 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Biocorp EU:ALCOR Euronext Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 35.10 28.50 35.10 0.00 01:00:00

BIOCORP: Its Range of Connected Devices Featured at Several International Conferences and Exhibitions

01/09/2022 6:30am

Business Wire


Biocorp (EU:ALCOR)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Biocorp Charts.

Regulatory News:

BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today its participation in the following trade shows:

  • Connect in Pharma (The Future of Packaging, Drug Delivery & Contract Manufacturing), September 14-15, 2022, Geneva, Switzerland
  • 2022 PDA (Universe of Pre-Filled Syringes and Injection Devices Conference), October 18-19, 2022, in Palm Springs, California (USA)
  • PODD (Partnerships Opportunities in Drug Delivery), October 24-25, 2022, Boston, Massachusetts (USA)
  • CPHI Worldwide, November 1-3, 2022, Frankfurt, Germany

Within the framework of these international exhibitions, BIOCORP will present its range of connected smart devices: the latest miniaturized versions of Mallya for injection pens, Injay for pre-filled syringes, as well as new products such as Sween, a reusable needle insertor to assist patients in the self-injection of drugs.

ABOUT BIOCORP

Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This smart sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of patients with diabetes. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 70 employees. BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR). For more information, please visit www.biocorpsys.com.

CONTACTS BIOCORP Sylvaine Dessard Marketing & Communication Director rp@biocorp.fr + 33 (0)6 88 69 72 85

CONTACTS ULYSSE COMMUNICATION Bruno ARABIAN barabian@ulysse-communication.com +33 (0)6 87 88 46 26

1 Year Biocorp Chart

1 Year Biocorp Chart

1 Month Biocorp Chart

1 Month Biocorp Chart